NPM1 and acute myeloid leukemia: Cytogenetic alterations, combined with mutations in nucleophosmin 1 (NPM1), CCAAT/enhancer-binding protein α (CEBPA), fms-like tyrosine kinase 3- internal tandem duplication (FLT3-ITD) and TP53, have been incorporated into the current prognostic grading system for patients with AML [7].